Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.710
+0.040 (1.09%)
At close: Aug 29, 2025, 4:00 PM
3.710
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:00 PM EDT
Arbutus Biopharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Arbutus Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $5.67, which forecasts a 52.83% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $7.00.
Price Target: $5.67 (+52.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arbutus Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +34.77% | Aug 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +34.77% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +34.77% | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +34.77% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +34.77% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
14.69M
from 6.17M
Increased by 138.02%
Revenue Next Year
3.73M
from 14.69M
Decreased by -74.63%
EPS This Year
-0.18
from -0.38
EPS Next Year
-0.19
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 17.0M | 7.4M | |
| Avg | 14.7M | 3.7M | |
| Low | 12.3M | 1.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 175.6% | -49.5% | |
| Avg | 138.0% | -74.6% | |
| Low | 98.5% | -92.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.16 | -0.18 | |
| Avg | -0.18 | -0.19 | |
| Low | -0.21 | -0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.